Zimmer price target raised to $131 from $110 at Canaccord Canaccord raised its price target on Zimmer Holdings to $131 from $110 to reflect the acquisition of Biomet. The firm sees a massive new knee product cycle and believes Zimmer is positioned solidly in the global musculoskeletal and OrthoRecon industry. Canaccord maintains its Buy rating on the stock.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.